Which has preferable valuation & earnings, ACHV or RGC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is ACHV or RGC more profitable?

Regencell Bioscience's return on equity of 0.00% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -511.12% -82.35% Regencell Bioscience N/A N/A N/A

Does the media favor ACHV or RGC?

In the previous week, Achieve Life Sciences had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Achieve Life Sciences and 3 mentions for Regencell Bioscience. Achieve Life Sciences' average media sentiment score of 0.59 beat Regencell Bioscience's score of 0.33 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MOR or ACHV?

Achieve Life Sciences has a consensus price target of $15.50, suggesting a potential upside of 109.18%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Achieve Life Sciences 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has better valuation and earnings, ACHV or MBX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A MBX Biosciences N/A N/A -$86.97M -$2.41 N/A

Is ACHV or MBX more profitable?

MBX Biosciences' return on equity of -26.02% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -511.12% -82.35% MBX Biosciences N/A -26.02% -24.94%

Does the media favor ACHV or MBX?

In the previous week, Achieve Life Sciences had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 5 mentions for Achieve Life Sciences and 2 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.16 beat Achieve Life Sciences' score of 0.59 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SUPN or ACHV?

In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 5 articles in the media. Achieve Life Sciences' average media sentiment score of 0.59 beat Supernus Pharmaceuticals' score of -0.46 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Achieve Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, HCM or ACHV?

HUTCHMED has higher revenue and earnings than Achieve Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.48 $456.91M N/A N/A Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A

Is HCM or ACHV more profitable?

HUTCHMED's return on equity of 0.00% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Achieve Life Sciences N/A -511.12% -82.35%

Does the media refer more to HCM or ACHV?

In the previous week, Achieve Life Sciences had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Achieve Life Sciences and 3 mentions for HUTCHMED. Achieve Life Sciences' average media sentiment score of 0.59 beat HUTCHMED's score of -0.20 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Achieve Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Achieve Life Sciences (ACHV) Competitors

$7.41 +0.22 (+3.06%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.32 -0.09 (-1.28%)

As of 10/9/2026 07:30 PM Eastern

Compare

ACHV vs. RGC, MOR, MBX, SUPN, and HCM

Should you buy Achieve Life Sciences stock or one of its competitors? Achieve Life Sciences's main competitors and comparable companies include Regencell Bioscience (RGC), MorphoSys (MOR), MBX Biosciences (MBX), Supernus Pharmaceuticals (SUPN), and HUTCHMED (HCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Achieve Life Sciences compare to Regencell Bioscience?

Achieve Life Sciences (NASDAQ:ACHV) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Regencell Bioscience's return on equity of 0.00% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
Regencell Bioscience	N/A	N/A	N/A

Achieve Life Sciences currently has a consensus target price of $15.50, suggesting a potential upside of 109.18%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Achieve Life Sciences is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Achieve Life Sciences has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

In the previous week, Achieve Life Sciences had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Achieve Life Sciences and 3 mentions for Regencell Bioscience. Achieve Life Sciences' average media sentiment score of 0.59 beat Regencell Bioscience's score of 0.33 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Achieve Life Sciences beats Regencell Bioscience on 8 of the 12 factors compared between the two stocks.

How does Achieve Life Sciences compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Achieve Life Sciences (NASDAQ:ACHV) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Achieve Life Sciences has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

In the previous week, Achieve Life Sciences had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Achieve Life Sciences and 0 mentions for MorphoSys. Achieve Life Sciences' average media sentiment score of 0.59 beat MorphoSys' score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Achieve Life Sciences	Positive

MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market.

Achieve Life Sciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Achieve Life Sciences' return on equity of -511.12% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Achieve Life Sciences	N/A	-511.12%	-82.35%

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Achieve Life Sciences has a consensus price target of $15.50, suggesting a potential upside of 109.18%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Achieve Life Sciences beats MorphoSys on 14 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to MBX Biosciences?

Achieve Life Sciences (NASDAQ:ACHV) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

MBX Biosciences is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Achieve Life Sciences has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

33.5% of Achieve Life Sciences shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Achieve Life Sciences currently has a consensus price target of $15.50, indicating a potential upside of 109.18%. MBX Biosciences has a consensus price target of $83.89, indicating a potential upside of 57.57%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Achieve Life Sciences is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Achieve Life Sciences had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 5 mentions for Achieve Life Sciences and 2 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.16 beat Achieve Life Sciences' score of 0.59 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences' return on equity of -26.02% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
MBX Biosciences	N/A	-26.02%	-24.94%

Summary

Achieve Life Sciences beats MBX Biosciences on 9 of the 14 factors compared between the two stocks.

How does Achieve Life Sciences compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Achieve Life Sciences (NASDAQ:ACHV) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Supernus Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market.

33.5% of Achieve Life Sciences shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 5 articles in the media. Achieve Life Sciences' average media sentiment score of 0.59 beat Supernus Pharmaceuticals' score of -0.46 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Achieve Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals presently has a consensus target price of $62.40, suggesting a potential upside of 46.24%. Achieve Life Sciences has a consensus target price of $15.50, suggesting a potential upside of 109.18%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Achieve Life Sciences has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Achieve Life Sciences	N/A	-511.12%	-82.35%

Supernus Pharmaceuticals has higher revenue and earnings than Achieve Life Sciences. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.46	-$38.55M	-$1.92	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

Summary

Achieve Life Sciences beats Supernus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Achieve Life Sciences compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Achieve Life Sciences (NASDAQ:ACHV) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

In the previous week, Achieve Life Sciences had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Achieve Life Sciences and 3 mentions for HUTCHMED. Achieve Life Sciences' average media sentiment score of 0.59 beat HUTCHMED's score of -0.20 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Achieve Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HUTCHMED has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market.

HUTCHMED presently has a consensus target price of $14.87, indicating a potential upside of 5.44%. Achieve Life Sciences has a consensus target price of $15.50, indicating a potential upside of 109.18%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

HUTCHMED has higher revenue and earnings than Achieve Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.48	$456.91M	N/A	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

HUTCHMED's return on equity of 0.00% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Achieve Life Sciences	N/A	-511.12%	-82.35%

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Achieve Life Sciences beats HUTCHMED on 8 of the 13 factors compared between the two stocks.

Get Achieve Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACHV vs. The Competition

Export

Metric	Achieve Life Sciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$739.87M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-4.78	797.58	274.15	26.16
Price / Sales	N/A	757.87	590.48	94.54
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	18.53	10.71	11.21	6.34
Net Income	-$54.65M	$2.84B	$3.50B	$381.90M
7 Day Performance	2.35%	-0.93%	-0.90%	-1.41%
1 Month Performance	1.79%	-4.91%	-4.44%	-3.48%
1 Year Performance	140.58%	-4.13%	6.96%	1.16%

Achieve Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACHV Achieve Life Sciences	3.011 of 5 stars	$7.41 +3.1%	$15.50 +109.2%	+125.9%	$739.87M	N/A	N/A	28
RGC Regencell Bioscience	0.389 of 5 stars	$6.12 -1.3%	N/A	-60.1%	$3.03B	N/A	N/A	10	News Coverage Earnings Report
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
MBX MBX Biosciences	3.0206 of 5 stars	$57.34 -0.3%	$77.00 +34.3%	+235.7%	$2.76B	N/A	N/A	63	Positive News
SUPN Supernus Pharmaceuticals	3.3479 of 5 stars	$44.00 -1.3%	$62.83 +42.8%	-13.8%	$2.56B	$718.95M	N/A	778

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACHV) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Achieve Life Sciences (ACHV) Competitors

ACHV vs. RGC, MOR, MBX, SUPN, and HCM

How does Achieve Life Sciences compare to Regencell Bioscience?

Summary

How does Achieve Life Sciences compare to MorphoSys?

Summary

How does Achieve Life Sciences compare to MBX Biosciences?

Summary

How does Achieve Life Sciences compare to Supernus Pharmaceuticals?

Summary

How does Achieve Life Sciences compare to HUTCHMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Achieve Life Sciences (ACHV) Competitors

ACHV vs. RGC, MOR, MBX, SUPN, and HCM

How does Achieve Life Sciences compare to Regencell Bioscience?

Which has preferable valuation & earnings, ACHV or RGC?

Is ACHV or RGC more profitable?

Do analysts rate ACHV or RGC?

Do institutionals & insiders hold more shares of ACHV or RGC?

Which has more volatility & risk, ACHV or RGC?

Does the media favor ACHV or RGC?

Summary

How does Achieve Life Sciences compare to MorphoSys?

Which has higher valuation and earnings, MOR or ACHV?

Does the media refer more to MOR or ACHV?

Which has more volatility & risk, MOR or ACHV?

Is MOR or ACHV more profitable?

Do institutionals and insiders have more ownership in MOR or ACHV?

Do analysts prefer MOR or ACHV?

Summary

How does Achieve Life Sciences compare to MBX Biosciences?

Which has better valuation and earnings, ACHV or MBX?

Which has more risk and volatility, ACHV or MBX?

Do institutionals and insiders believe in ACHV or MBX?

Do analysts rate ACHV or MBX?

Does the media favor ACHV or MBX?

Is ACHV or MBX more profitable?

Summary

How does Achieve Life Sciences compare to Supernus Pharmaceuticals?

Which has more volatility & risk, SUPN or ACHV?

Do institutionals & insiders hold more shares of SUPN or ACHV?

Does the media prefer SUPN or ACHV?

Do analysts rate SUPN or ACHV?

Is SUPN or ACHV more profitable?

Which has higher earnings and valuation, SUPN or ACHV?

Summary

How does Achieve Life Sciences compare to HUTCHMED?

Does the media refer more to HCM or ACHV?

Which has more risk and volatility, HCM or ACHV?

Do analysts prefer HCM or ACHV?

Which has higher valuation & earnings, HCM or ACHV?

Is HCM or ACHV more profitable?

Do insiders and institutionals hold more shares of HCM or ACHV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools